

Form 605

Corporations Act 2001
Section 671B

Notice of ceasing to be a substantial holder

To Company Name/Scheme	PYC Therapeutics Ltd
ACN/ARSN	098 391 961

1. Details of substantial holder (1)

Name	Retail Employees Superannuation Pty Limited (in its capacity as trustee of the Retail Employee Superannuation Trust)
ACN/ARSN (if applicable)	001 987 739

The holder ceased to be a substantial holder on	31 / 08 / 2026
The previous notice was given to the company on	16 / 06 / 2026
The previous notice was dated	12 / 06 / 2026

2. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest (2) of the substantial holder or an associate (3) in voting securities of the company or scheme, since the substantial shareholder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (4)	Consideration given in relation to change (5)	Class (6) and number of securities affected	Person's votes affected
31/08/2026	Retail Employees Superannuation Pty Limited (in its capacity as trustee of the Retail Employee Superannuation Trust)	Sell	As Attached	As Attached	Retail Employees Superannuation Pty Limited (in its capacity as trustee of the Retail Employee Superannuation Trust)

3. Change in association

The persons who have become associates (3) of, ceased to be associates of, or have changed the nature of their association (7) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
N/A	N/A

4. Addresses

The addresses of persons named in this form are as follows:

Name	Address
Retail Employees Superannuation Pty Limited	Level 21, 50 Bridge Street, Sydney NSW 2000
State Street Australia Limited	420 George Street, Sydney, NSW, 2000

Signature

print name	Jolanta Willetts	capacity	Company Secretary		
sign here	Signed by:  55561182EBFC44E...	date	02	/	09 / 2026

DIRECTIONS

- (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 4 of the form.
- (2) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
- (3) See the definition of "associate" in section 9 of the Corporations Act 2001.
- (4) Include details of:

(a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and

(b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.
- (5) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
- (6) The voting shares of a company constitute one class unless divided into separate classes.
- (7) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.

Trade Date	Security Long Name	CUSIP NUMBER	Transaction Category Name	Shares/Par Value	Base Net Amount
06/15/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	12,186	14,914.12
06/15/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	174,449	213,503.38
06/16/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	9,398	11,772.77
06/16/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	134,542	168,539.22
06/17/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	6,727	8,630.77
06/17/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	96,308	123,563.68
07/24/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	44,531	74,624.00
07/30/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	SELL	44,531	72,362.88
07/30/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	44,531	72,362.88
04/08/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	SELL	44,531	88,794.33
08/31/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	SELL	208,368	476,479.96
08/31/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	SELL	169,711	393,124.17
08/31/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	SELL	2,339,154	5,348,998.06
08/31/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	SELL	1,905,178	4,413,217.19